The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a more substantial reduction in body weight and enhance metabolic heal